Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Villejuif – page 72

929 clinical trials in Villejuif, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Villejuif at a glance
929
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

929 trials in Villejuif

Open in trial search

Myelofibrosis

Not recruiting

Study of BMS-986158 Alone and with Ruxolitinib or Fedratinib for Patients with Intermediate or High Risk Myelofibrosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fedratinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Renal cell carcinoma

Not recruiting

Study of Pembrolizumab, Favezelimab, and Lenvatinib for Patients with Renal Cell Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

K-ras gene mutation

Not recruiting

Study of BMS-986466 with Adagrasib and Cetuximab for Patients with KRAS G12C-mutant Advanced Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Metastatic malignant melanoma

Not recruiting

Study on the Safety and Effectiveness of Pembrolizumab, Lenvatinib, and Quavonlimab for Patients with Advanced Melanoma with Brain Metastases

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Merck Sharp & Dohme LLC

Malignant melanoma

Not recruiting

Study of LTX-315 and Pembrolizumab for Patients with Advanced Melanoma Resistant to PD-1/PD-L1 Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Chlorphenamine
  • Sponsor:Lytix Biopharma AS

Gastrointestinal stromal tumour

Not recruiting

Study of CGT9486 and Sunitinib for Patients with Advanced Gastrointestinal Stromal Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sunitinib
  • Sponsor:Cogent Biosciences Inc.

Squamous cell carcinoma of head and neck+2

Not recruiting

Study of BGB-A425, LBL-007, and Tislelizumab for Patients with Advanced Head and Neck Cancer, Lung Cancer, or Kidney Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lbl-007
  • Sponsor:Beigene Ltd.

Hepatic cancer

Not recruiting

Study on Adding Ipilimumab to Atezolizumab and Bevacizumab for Patients with Liver Cancer Receiving First-Line Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Fondation Franc.Cancerologie Digestive

Metastatic malignant melanoma

Not recruiting

Study on Botensilimab and Balstilimab for Patients with Advanced Melanoma Resistant to Previous Treatments

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Balstilimab
  • Sponsor:Agenus Inc.

Hodgkin's disease

Not recruiting

Study Comparing Pembrolizumab and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Brentuximab Vedotin
  • Sponsor:Merck Sharp & Dohme LLC

T-cell lymphoma

Not recruiting

Study of Tolinapant with Decitabine and Cedazuridine for Patients with Relapsed or Refractory Peripheral T-cell Lymphoma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cedazuridine
  • Sponsor:Taiho Oncology Inc.

Hepatocellular carcinoma

Not recruiting

Study of Ezurpimtrostat with Atezolizumab and Bevacizumab for Patients with Unresectable Liver Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Centre Hospitalier Universitaire Grenoble Alpes

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Villejuif

What the registry says about research in the country

01 Oncology - Head and Neck Cancer

Innovative research focusing on locally advanced head and neck squamous cell carcinoma treatments, including novel therapies combined with radiotherapy and immunotherapy approaches.

  • NBTXR3 with radiotherapy
  • EGFR-ADC therapy combinations
  • HPV-positive oropharyngeal cancer
02 Gastrointestinal Oncology

Studies targeting various digestive system cancers, with particular focus on pancreatic adenocarcinoma and advanced gastric cancer treatments.

  • Anti-CEACAM5 ADC therapy
  • Sotorasib combinations
  • Novel gastrointestinal cancer treatments
03 Hematologic Malignancies

Cutting-edge research in multiple myeloma treatment, exploring new combination therapies and maintenance approaches.

  • Elranatamab-lenalidomide therapy
  • Belantamab mafodotin combinations
  • T-cell lymphoma treatments
04 Lung Cancer Research

Comprehensive studies in both non-small cell lung cancer and small cell lung cancer, investigating targeted therapies and immunotherapy combinations.

  • Novel antibody-drug conjugates
  • Microbiome-based approaches
  • Targeted therapy combinations
05 Advanced Solid Tumors

Broad-spectrum research investigating novel treatments for metastatic solid tumors, including innovative therapeutic approaches and combination strategies.

  • PARG inhibitor studies
  • Targeted molecular therapies
  • Immunotherapy combinations
Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.